A recent study published in the Journal of Hematology & Oncology investigated the expression of immune checkpoint proteins PD-1 and PD-L1 in thymic epithelial tumors (TETs). Involving 70 patients, the researchers utilized immunohistochemistry to evaluate expression patterns. Findings revealed that PD-1 was commonly located in immune cells, while PD-L1 was predominantly found in tumor cells, with over 80 percent of thymic carcinomas showing high PD-L1 expression. This may aid in diagnosis and treatment, though further research is required to validate prognostic implications. Standardization of PD-L1 testing is recommended to enhance consistency in results.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
